Cingulate (CING) Operating Expenses (2021 - 2026)
Cingulate's (CING) quarterly Operating Expenses came in at $6.3 million in Q4 2025, up 1.24% YoY from $6.2 million in Q4 2024, and up 4.83% on a QoQ basis from $6.0 million in Q3 2025.
Cingulate (CING) Operating Expenses (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Operating Expenses data on file, last reported at $6.3 million in Q4 2025.
- Quarterly Operating Expenses rose 1.24% year-over-year to $6.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.0 million (up 2.19% YoY) and the FY2025 annual result came in at $19.9 million, up 27.44% from the prior year.
- Operating Expenses climbed to $6.3 million in Q4 2025, from $6.0 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $15.3 million in Q3 2021 to a low of $1.3 million in Q1 2021.
- A 5-year average of $4.9 million and a median of $4.0 million in 2022 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 276.6% in 2022, down 74.03% in 2022.
- Tracing CING's Operating Expenses over 5 years: stood at $2.6 million in 2021, then surged by 69.05% to $4.5 million in 2022, then surged by 51.89% to $6.8 million in 2023, then decreased by 8.66% to $6.2 million in 2024, then increased by 1.24% to $6.3 million in 2025.
- The last three Operating Expenses figures came in at $6.3 million (Q4 2025), $6.0 million (Q3 2025), and $3.7 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Cingulate | 70.68 Mn | 70.68 Mn | - | 5.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.41 Mn |
| Dec 31, 2025 | 6.29 Mn |
| Sep 30, 2025 | 6.00 Mn |
| Mar 31, 2025 | 3.71 Mn |
| Dec 31, 2024 | 6.21 Mn |
| Sep 30, 2024 | 3.28 Mn |
| Jun 30, 2024 | 3.21 Mn |
| Mar 31, 2024 | 2.95 Mn |
| Dec 31, 2023 | 6.80 Mn |
| Sep 30, 2023 | 5.75 Mn |
| Jun 30, 2023 | 6.36 Mn |
| Mar 31, 2023 | 3.85 Mn |
| Dec 31, 2022 | 4.48 Mn |
| Sep 30, 2022 | 3.97 Mn |
| Jun 30, 2022 | 4.05 Mn |
| Mar 31, 2022 | 5.01 Mn |
| Dec 31, 2021 | 2.65 Mn |
| Sep 30, 2021 | 15.28 Mn |
| Jun 30, 2021 | 1.42 Mn |
| Mar 31, 2021 | 1.33 Mn |